Sponsors (11)
The bill aligns federal research funding and institutional practice with ethical concerns about tissue from induced abortions and clarifies rules, but does so at the risk of reducing access to fetal tissue for research, imposing compliance costs, and potentially slowing or shifting important biomedical research away from U.S. institutions.
Scientists and patients: researchers can develop and use non-fetal-derived, high-efficiency cell lines for vaccines and vectors, enabling continued vaccine and therapeutic research without relying on tissue from induced abortions.
Taxpayers, researchers, and hospitals: federal funding/support is restricted for research using tissue from induced abortions and institutions that avoid such tissue are protected from association, aligning federal support with the ethical preferences of some citizens.
Scientists and hospitals: the bill preserves a narrow, regulated pathway to conduct and fund research using fetal tissue from miscarriages or stillbirths under PHSA §498A, allowing some studies that depend on that source to continue.
Scientists, hospitals, and patients: loss of access to fetal tissue from induced abortions will hinder studies (e.g., developmental biology, some vaccine research), delaying or blocking research that can lead to new treatments.
Patients and researchers: if non-fetal-derived cell lines are not equivalent, research capacity may be reduced and vaccine/therapeutic development delayed, harming patients who need timely advances.
Federal agencies, researchers, and hospitals: new compliance burdens, narrower authorization pathways, and administrative complexity (including PHSA §498A procedures) will raise costs and slow authorized research.
Based on analysis of 3 sections of legislative text.
Bars federal support for research using fetal tissue from induced abortions, narrows permitted fetal‑tissue research to miscarriage/stillbirth tissue, and tightens donation prohibitions.
Official title: Prohibit the Federal Government from conducting, funding, approving, or otherwise supporting any research involving human fetal tissue that is obtained pursuant to an induced abortion, and to prohibit the solicitation or knowing acquisition, receipt, or acceptance of a donation of such issue.
Introduced March 12, 2025 by Cindy Hyde-Smith · Last progress March 12, 2025
Prohibits all federal departments and agencies from conducting, funding, approving, or otherwise supporting any research that uses human fetal tissue obtained from an induced abortion, while preserving authority to develop alternative non‑fetal high‑efficiency cell lines. Allows federal research on fetal tissue from miscarriages or stillbirths under revised and narrowed statutory definitions and restrictions. Also tightens criminal/prohibitory language to bar soliciting or accepting fetal tissue when the donor knew the pregnancy was intentionally initiated to provide tissue or when the tissue came from an induced abortion, and makes related conforming amendments to existing law.